Biogen Inc on Thursday said getting hospitals and clinics to use its new Alzheimer's disease drug Aduhelm and insurers to reimburse it has been slower than it expected, as controversy mounts over the U.S. Food and Drug Administration's approval process for the treatment. The FDA decided to approve the drug against the recommendation of a panel of outside experts convened to advise the regulator. Some prominent doctors, hospitals and health insurers have criticized the FDA's approval and said they will not offer the drug. Biogen had previously said 900 medical centers would be ready to administer the drug shortly after its launch. That does not mean the remaining 65% have decided not to use the drug, Biogen executives said, adding it was still early days in the drug's launch.

Source: Mint July 22, 2021 15:33 UTC